Cue biopharma announces clinical trial collaboration agreement with merck

Cue biopharma announces clinical trial collaboration agreement with merck to evaluate cue-101 in combination with keytruda® (pembrolizumab) as first-line treatment for hpv+ recurrent/metastatic head and neck cancer.cue biopharma inc - cue biopharma will conduct a phase 1 study, keynote-a78.cue biopharma inc - keynote-a78 will be conducted in parallel with ongoing phase 1 monotherapy study of cue-101 post first-line treatment.cue biopharma - early monotherapy pk data from first two dosing cohorts demonstrates dose-related drug exposure consistent with preclinical modeling.cue biopharma inc - cue biopharma expects to report initial pharmacodynamic data from phase 1 monotherapy portion of study in first half of 2020.
CUE Ratings Summary
CUE Quant Ranking